Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion

Astolfi, Annalisa; Masetti, Riccardo; Indio, Valentina; Bertuccio, Salvatore Nicola; Messelodi, Daria; Rampelli, Simone; Leardini, Davide; Carella, Matteo; Serravalle, Salvatore; Libri, Virginia; Bandini, Jessica; Volinia, Stefano; Candela, Marco; Pession, Andrea

doi:10.1182/blood.2021011677

Cited by 27 publications

(32 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detailed treatment and outcome of the 3 patients are shown in Table 1. Transplantation was rarely used as a modality for vAPL, given the short-term followup and small number of the cases, but the benefit has been discussed in some variants with the high relapse rate, like STAT5B-RARA (9) and very young cases, like TTMV-RARA (7). Our patient had even stronger indications for transplantation due to complicated chromosome karyotype and poorly prognostic mutated genes.…”

Section: Discussionmentioning

confidence: 89%

“…The outcome seems to be suboptimal in a number of cases with poor response to ATRA and ATO, such as ZBTB16-RARA. Still, fusions, such as NPM1-RARA and FIP1L1-RARA, are sensitive to ATRA, and fusions, such as TTMV-RARA, are sensitive to both ATRA and ATO combination therapy (4,7). Generally, these variants should be treated with a combination of ATRA and chemotherapy (anthracyclines), with the possible use of AML protocols in known resistant variants (4,8,9).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Successful therapy with all-trans retinoic acid combined with chemotherapy followed by hematopoietic stem cell transplantation for acute promyelocytic leukemia carrying the BCOR-RARA fusion gene

Chen

Zhu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is characterized by the balanced translocation of chromosomes 15 and 17, resulting in the formation of PML-RARA fusion gene. More than 98% of APL have PML-RARA fusion, and less than 2% have other types of RARA gene partners, which named variant APL (vAPL). In the present study, we reported a vAPL with BCOR-RARA, which was the third case of BCOR-RARA APL published. The patient achieved complete remission (CR) with all-trans retinoic acid (ATRA) monotherapy, and molecular CR with ATRA plus standard chemotherapy. After that, he underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and ATRA maintenance and maintained a molecular CR status. This case provided valuable insights into the accurate identification of vAPL. Moreover, ATRA combined with chemotherapy followed by allo-HSCT was suggested as an optimal choice for those vAPL patients who had a high risk of relapse.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Case Report: Successful therapy with all-trans retinoic acid combined with chemotherapy followed by hematopoietic stem cell transplantation for acute promyelocytic leukemia carrying the BCOR-RARA fusion gene

Chen

Zhu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In our cohort, viral reads were detected in 1346 (72.0%) cases. Particularly prevalent were torque teno viruses, which are extremely common in humans 24 and have very recently been implicated in a childhood APL case harboring a torque teno mini virus/RARA chimeric transcript 25 , and human herpesviruses (Fig. 2a ).…”

Section: Resultsmentioning

confidence: 99%

Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes

et al. 2022

View full text Add to dashboard Cite

Although recent work has described the microbiome in solid tumors, microbial content in hematological malignancies is not well-characterized. Here we analyze existing deep DNA sequence data from the blood and bone marrow of 1870 patients with myeloid malignancies, along with healthy controls, for bacterial, fungal, and viral content. After strict quality filtering, we find evidence for dysbiosis in disease cases, and distinct microbial signatures among disease subtypes. We also find that microbial content is associated with host gene mutations and with myeloblast cell percentages. In patients with low-risk myelodysplastic syndrome, we provide evidence that Epstein-Barr virus status refines risk stratification into more precise categories than the current standard. Motivated by these observations, we construct machine-learning classifiers that can discriminate among disease subtypes based solely on bacterial content. Our study highlights the association between the circulating microbiome and patient outcome, and its relationship with disease subtype.

show abstract

“…The significance of USP11 in glioma tumorigenesis has been demonstrated by its positive regulation on PML, which is downregulated in majority of cancers and played inhibiting cancer role [ 108 , 109 ]. Hsin-Chieh Wu et al [ 33 ] found that USP11 inhibits the occurrence and progression of glioma via deubiquitinating and stabilizing PML.…”

Section: Usp11 In Cancersmentioning

confidence: 99%

Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management

et al. 2022

View full text Add to dashboard Cite

Ubiquitination is a critical biological process in post-translational modification of proteins and involves multiple signaling pathways in protein metabolism, apoptosis, DNA damage, cell-cycle progression, and cancer development. Deubiquitinase, a specific enzyme that regulates the ubiquitination process, is also thought to be closely associated with the development and progression of various cancers. In this article, we systematically review the emerging role of the deubiquitinase ubiquitin-specific peptidase 11 (USP11) in many cancer-related pathways. The results show that USP11 promotes or inhibits the progression and chemoresistance of different cancers, including colorectal, breast, ovarian, and hepatocellular carcinomas, via deubiquitinating several critical proteins of cancer-related pathways. We initially summarize the role of USP11 in different cancers and further discuss the possibility of USP11 as a therapeutic strategy.

show abstract

Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion

Cited by 27 publications

References 21 publications

Case Report: Successful therapy with all-trans retinoic acid combined with chemotherapy followed by hematopoietic stem cell transplantation for acute promyelocytic leukemia carrying the BCOR-RARA fusion gene

Case Report: Successful therapy with all-trans retinoic acid combined with chemotherapy followed by hematopoietic stem cell transplantation for acute promyelocytic leukemia carrying the BCOR-RARA fusion gene

Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes

Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management

Contact Info

Product

Resources

About